GlassScriptPhysician profile
Gloria Lu
NPI 1932589108
$4,915.90
in general payments reported to CMS, 2019-2025
33 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $466 · 2022: $317 · 2023: $1,241 · 2024: $1,123 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $792.96 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.44 | 2019-2024 | Jardiance, Spiriva Respimat, Ofev |
| Lilly USA, LLC | $420.80 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $393.71 | 2023-2024 | |
| Glaxosmithkline, LLC. | $391.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Novo Nordisk INC | $350.51 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $343.28 | 2019-2024 | Capvaxive, Vaxelis, Gardasil 9 |
| Pfizer INC. | $255.49 | 2019-2025 | |
| Amgen INC. | $222.32 | 2019-2024 | Otezla, Repatha, Tezspire |
| Sanofi-Aventis U.S. LLC | $198.22 | 2019-2022 | |
| Sk Life Science, INC. | $161.70 | 2023-2024 | |
| Allergan, INC. | $148.93 | 2020 | |
| Gilead Sciences, INC. | $118.00 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $78.58 | 2019 | |
| Sanofi Pasteur INC. | $63.52 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.13 | 2023-2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $45.03 | 2022 | |
| Mdd US Operations, LLC | $39.36 | 2023 | Gocovri |
| Bausch Health US, LLC | $26.45 | 2023 | Aplenzin |
| Biogen, INC. | $26.20 | 2023 | Vumerity, Tysabri |
| Dexcom, INC. | $25.37 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $24.21 | 2024 | Heplisav-B |
| Neurocrine Biosciences, INC. | $24.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.88 | 2020 | |
| Amarin Pharma, INC. | $23.71 | 2020 | |
| Hologic Sales and Service, LLC | $22.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.55 | 2022 | |
| Medtronic, INC. | $19.00 | 2023 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $18.92 | 2023 | Quviviq |
| Metuchen Pharmaceuticals | $18.61 | 2019 | |
| Seqirus USA INC | $17.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.18 | 2019 | |
| Fidia Pharma USA INC. | $12.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.